Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Kuperman (NPI 1093849432)

Field	Value
Entity Type	Individual
Organization	David Kuperman
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 16, 2007

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider is effectively single-payer in the dataset: Total Medicare revenue is $1.9M and there is no Medicaid billing on file. The absence of Medicaid activity indicates the provider’s revenue exposure is concentrated in Medicare rather than split across both public programs.

Revenue concentration is high: the top 3 Medicare codes by revenue — J9271 (52.2%), J9299 (19.7%), and J0897 (6.8%) — together account for 78.8% of this provider’s Medicare revenue. J9271 alone represents $989K of the Medicare total, signaling reliance on a single high-revenue drug.

The code mix indicates an outpatient oncology infusion practice with a focus on high-cost immunotherapy and supportive oncology agents: J9271 (pembrolizumab) and J9299 (nivolumab) are the top revenue drivers, complemented by chemotherapy administration codes such as 96413 and infusion/support codes like J0897 (denosumab), J1437 (ferric derisomaltose), and J0885 (epoetin alfa). This mix is consistent with regular on‑site infusions, anemia and bone-health supportive care, and integrated chemotherapy services.

Competitive standing for the primary biologics is mixed: J9271 ranks #277 of 1841 providers (85th percentile; typical, unremarkable volume) indicating above-average but not dominant national activity for pembrolizumab, while J9299 ranks #218 of 505 (57th percentile; typical, unremarkable volume) showing more middle-of-market volume for nivolumab. J0897 ranks #1807 of 10057 (82th percentile; typical, unremarkable volume), which points to a solid national footprint for denosumab relative to the broader provider base.

Clinical throughput and office-based E/M activity are notable: 99214 generated 711 claims and $61.1K (3.2% of Medicare revenue) and ranks in the 95th percentile (notably above typical national volume), and 96413 generated 586 claims and $51K (2.7% of Medicare revenue) and ranks in the 94th percentile (notably above typical national volume). These labels indicate sustained, above-typical outpatient visit and chemotherapy-administration volumes that align with an active oncology clinic and infusion suite.

Several ancillary services and point-of-care procedures support the infusion practice: 85025 (CBC) shows 1.6K claims and $13.2K revenue and ranks in the 96th percentile (typical, unremarkable volume), 36415 (venipuncture) shows 1.5K claims and $11.7K revenue and ranks in the 98th percentile (typical, unremarkable volume), and 80053 (CMP) shows 1.2K claims and $11.7K revenue and ranks in the 95th percentile (typical, unremarkable volume). These volumes are consistent with routine lab monitoring and phlebotomy tied to ongoing infusion therapy.

There are specific statistical outliers in the procedural mix that imply sustained infusion activity: 96375 (sequential IV push) is in the 96th percentile and labeled notably above typical national volume, while 96365 and addons like 96417 and 96415 also appear in mid-to-high percentiles. Those labels, combined with the high share of revenue from biologics, underscore that infusion and drug administration are central to this provider’s revenue model.

Tenure and practice stability are evident: the NPI was enumerated on 2007-03-16 (~19 years ago), indicating a long-standing presence in the market. Long tenure plus the pattern of high-volume infusion and E/M codes suggests an established outpatient hematology/oncology practice with sustained Medicare-facing operations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	23,000	$40	$989K
J9299	Injection, nivolumab, 1 mg	16,200	$20	$372.6K
J0897	Injection, denosumab, 1 mg	7,200	$20	$129.6K
J1437	Injection, ferric derisomaltose, 10 mg	4,300	$20	$73.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	710	$90	$61.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$90	$51K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	7,620	$10	$45.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	220	$120	$27.4K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	170	$130	$22.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	300	$60	$16.8K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

David Kuperman — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	40	20,700	$40	$896.3K
J9299	13	30	15,660	$20	$432.9K
J1437	16	20	6,450	$20	$107.8K
J0897	35	160	2,580	$20	$89.7K
J0885	14	40	4,070	$10	$38K
96413	25	80	380	$90	$36.6K
J9217	12	50	100	$130	$20K
99214	411	4,300	130	$70	$18.8K
99233	869	960	130	$90	$18.2K
99232	779	1,450	130	$60	$14.7K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Kuperman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0
Lawrence Mendelsohn	AR	Hematology & Oncology Physician	$3.4M	$0
Jamie Burton	AR	Hematology & Oncology Physician	$2.8M	$0
Kewen Jauss	AR	Hematology & Oncology Physician	$2.8M	$0
Mariann Harrington	AR	Hematology & Oncology Physician	$2.7M	$0
Appalanaidu Sasapu	AR	Hematology & Oncology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as David Kuperman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

David Kuperman — Billing Profile & Reimbursement Data

Sign up for David Kuperman — Billing Profile & Reimbursement Data policy alerts

David Kuperman — Billing Profile & Reimbursement Data

Sign up for David Kuperman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References